ConductScience.org, home

Paper4348752

The use of drugs in combination for the treatment of cancer: rationale and results.

DeVita VT and 1 other. N Engl J Med, 1973. Cited by 192 papers, by iCite.

Cite this record

ConductScience Library. The use of drugs in combination for the treatment of cancer: rationale and results. Papers, record 4348752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4348752

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The use of drugs in combination for the treatment of cancer: rationale and results.
PubMed
Journal
N Engl J Med
PubMed
Year
1973
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
192
iCite
Relative citation ratio, by iCite
4.33
iCite
Revised in PubMed
2007-11-15
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1DeVita VTV T
2Schein PSP S

Source PubMed

Download CSV of authors

Topics23

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
NeoplasmsMajor topic
Animals
Breast Neoplasms
Child
Dose-Response Relationship, Drug
Drug Resistance
Drug Synergism
Female
Gastrointestinal Neoplasms
Hodgkin Disease
Humans
Leukemia L1210
Leukemia, Lymphoid
Leukemia, Myeloid, Acute
Lymphoma
Male
Models, Biological
Neuroblastoma
Remission, Spontaneous
Testicular Neoplasms
Time Factors
Wilms Tumor

Source PubMed

Download CSV of topics

Cited by39

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 192 citations.

PMIDTitleJournalYearIn PapersSource
42054999Rethinking the role of synergy calculations in the next century of drug combination discovery.Med2026https://conductscience.org/library/papers/42054999PubMed
40088336Predicting Synergistic Drug Combinations Based on Fusion of Cell and Drug Molecular Structures.Interdiscip Sci2025https://conductscience.org/library/papers/40088336PubMed
37974028Additivity predicts the efficacy of most approved combination therapies for advanced cancer.Nat Cancer2023https://conductscience.org/library/papers/37974028PubMed
37121274High-throughput approaches to uncover synergistic drug combinations in leukemia.SLAS Discov2023https://conductscience.org/library/papers/37121274PubMed
36685168Combination Chemotherapy of Multidrug-resistant Early-stage Colon Cancer: Determining Optimal Dose Schedules by High-performance Computer Simulation.Cancer Res Commun2023https://conductscience.org/library/papers/36685168PubMed
34983746Independent Drug Action in Combination Therapy: Implications for Precision Oncology.Cancer Discov2022https://conductscience.org/library/papers/34983746PubMed
34670583Prediction of synergistic drug combinations using PCA-initialized deep learning.BioData Min2021https://conductscience.org/library/papers/34670583PubMed
32774773cGAS-STING pathway in oncogenesis and cancer therapeutics.Oncotarget2020https://conductscience.org/library/papers/32774773PubMed
31032838CANCROX: a cross-species cancer therapy database.Database (Oxford)2019https://conductscience.org/library/papers/31032838PubMed
30203598In Vivo Anticancer Activity of a Nontoxic Inert Phenolato Titanium Complex: High Efficacy on Solid Tumors Alone and Combined with Platinum Drugs.ChemMedChem2018https://conductscience.org/library/papers/30203598PubMed
29245008On the Design of Combination Cancer Therapy.Cell2017https://conductscience.org/library/papers/29245008PubMed
28446463The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.Cancer Res2017https://conductscience.org/library/papers/28446463PubMed
28376154Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival.J Natl Cancer Inst2017https://conductscience.org/library/papers/28376154PubMed
27641330Translational research in neuroendocrine tumors: pitfalls and opportunities.Oncogene2017https://conductscience.org/library/papers/27641330PubMed
26088171Preclinical optimization of a broad-spectrum anti-bladder cancer tri-drug regimen via the Feedback System Control (FSC) platform.Sci Rep2015https://conductscience.org/library/papers/26088171PubMed
25493378Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer.Braz J Med Biol Res2015https://conductscience.org/library/papers/25493378PubMed
23998076Tackling the problems of tumour chemotherapy by optimal drug scheduling.J Clin Diagn Res2013https://conductscience.org/library/papers/23998076PubMed
23805101Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy.Front Pharmacol2013https://conductscience.org/library/papers/23805101PubMed
23164555Understanding resistance to combination chemotherapy.Drug Resist Updat2012https://conductscience.org/library/papers/23164555PubMed
22733553Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives.EMBO Mol Med2012https://conductscience.org/library/papers/22733553PubMed

See all 39 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/4348752

GET https://conductscience.org/api/papers/v1/4348752/cited_by?page=2